Biopharma Analysis Infinitylab Now Meets All Bio-Analysis Needs of Pharmaceutical Companies
Santa Clara/USA — With the launch of three Infinitylab Bio LC systems, Agilent Technologies wants to specifically address the needs of the biopharma industry. The release is central to the company's portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that seamlessly integrate with Agilent Openlab and Masshunter software, and Crosslab services to maximize efficiency in biopharma labs.
The three new systems include
- the 1290 Infinity II Bio LC System with High-Speed Pump,
- the 1290 Infinity II Bio LC System with Flexible Pump, and
- the 1260 Infinity II Prime Bio LC System.
These systems are based on the Infinitylab LC technology and were designed to help future-proof laboratories by providing a universal LC platform that delivers Infinitylab LC reliability and performance with additional bio-analysis capability and even greater resistance to harsh analytical conditions.
Stefan Schuette, vice president, and general manager of Agilent’s Liquid Phase Separations Division: “By offering new instruments, columns, application kits, and supplies we're providing solutions that customers can tailor to meet their specific bio-analytical requirements, including seamless transfer of existing methods from both Agilent and non-Agilent LC systems.”
The company also announced the planned release of several new workflow solutions based on the Bio LC core systems. These specialized solutions include a new, biocompatible 2D-LC, method development, and a new Online LC solution for process monitoring and process analytical technology (PAT). These new solutions will complement already existing bio-analytical LC/Q-TOF MS, SEC (Size Exclusion Chromatography) and bio-purification solutions from Agilent.